{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:39:48Z","timestamp":1791585588810,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1038\/s41380-020-00913-1","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T04:07:18Z","timestamp":1603080438000},"page":"3419-3429","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2612-4119","authenticated-orcid":false,"given":"Francesco","family":"Bartoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5392-6398","authenticated-orcid":false,"given":"B\u0142a\u017cej","family":"Misiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-5331","authenticated-orcid":false,"given":"Tommaso","family":"Callovini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5342-9394","authenticated-orcid":false,"given":"Daniele","family":"Cavaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5718-9930","authenticated-orcid":false,"given":"Riccardo M.","family":"Cioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-2107","authenticated-orcid":false,"given":"Cristina","family":"Crocamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8143-182X","authenticated-orcid":false,"given":"Jonathan B.","family":"Savitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6877-6169","authenticated-orcid":false,"given":"Giuseppe","family":"Carr\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"913_CR1","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bdi.12423","volume":"18","author":"AJ Ferrari","year":"2016","unstructured":"Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18:440\u201350.","journal-title":"Bipolar Disord"},{"key":"913_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1906193","volume":"383","author":"AF Carvalho","year":"2020","unstructured":"Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020;383:58\u201366.","journal-title":"N Engl J Med"},{"key":"913_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tins.2017.10.006","volume":"41","author":"PJ Harrison","year":"2018","unstructured":"Harrison PJ, Geddes JR, Tunbridge EM. The emerging neurobiology of bipolar disorder. Trends Neurosci. 2018;41:18\u201330.","journal-title":"Trends Neurosci"},{"key":"913_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/pcn.12476","volume":"71","author":"E Sigitova","year":"2017","unstructured":"Sigitova E, Fi\u0161ar Z, Hroudov\u00e1 J, Cik\u00e1nkov\u00e1 T, Raboch J. Biological hypotheses and biomarkers of bipolar disorder. Psychiatry Clin Neurosci. 2017;71:77\u2013103.","journal-title":"Psychiatry Clin Neurosci"},{"key":"913_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/mp.2009.39","volume":"14","author":"C Langan","year":"2009","unstructured":"Langan C, McDonald C. Neurobiological trait abnormalities in bipolar disorder. Mol Psychiatry. 2009;14:833\u201346.","journal-title":"Mol Psychiatry"},{"key":"913_CR6","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1007\/s00213-019-5175-x","volume":"236","author":"JD Rosenblat","year":"2019","unstructured":"Rosenblat JD. Targeting the immune system in the treatment of bipolar disorder. Psychopharmacology. 2019;236:2909\u201321.","journal-title":"Psychopharmacology"},{"key":"913_CR7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jpsychires.2017.03.018","volume":"92","author":"P Sayana","year":"2017","unstructured":"Sayana P, Colpo G, Sim\u00f5es L, Vayalanellore Giridharan V, Teixeira A, Quevedo J, et al. A systemic review of evidence for the role of inflammatory biomarkers in bipolar patients. J Psychiatr Res. 2017;92:160\u201382.","journal-title":"J Psychiatr Res"},{"key":"913_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.neuropharm.2016.01.011","volume":"112","author":"H Fujigaki","year":"2017","unstructured":"Fujigaki H, Yamamoto Y, Saito K. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology. 2017;112:264\u201374.","journal-title":"Neuropharmacology"},{"key":"913_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.psyneuen.2010.09.012","volume":"36","author":"R Dantzer","year":"2011","unstructured":"Dantzer R, O\u2019Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36:426\u201336.","journal-title":"Psychoneuroendocrinology"},{"key":"913_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s41380-019-0414-4","volume":"25","author":"J Savitz","year":"2020","unstructured":"Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020;25:131\u201347.","journal-title":"Mol Psychiatry"},{"key":"913_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrn3257","volume":"13","author":"R Schwarcz","year":"2012","unstructured":"Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci. 2012;13:465\u201377.","journal-title":"Nat Rev Neurosci"},{"key":"913_CR12","doi-asserted-by":"publisher","first-page":"eaaf9794","DOI":"10.1126\/science.aaf9794","volume":"357","author":"I Cervenka","year":"2017","unstructured":"Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: tryptophan\u2019s metabolites in exercise, inflammation, and mental health. Science. 2017;357:eaaf9794.","journal-title":"Science"},{"key":"913_CR13","doi-asserted-by":"publisher","first-page":"12884","DOI":"10.1523\/JNEUROSCI.4101-07.2007","volume":"27","author":"GJ Guillemin","year":"2007","unstructured":"Guillemin GJ, Cullen KM, Lim CK, Smythe GA, Garner B, Kapoor V, et al. Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007;27:12884\u201392.","journal-title":"J Neurosci"},{"key":"913_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnins.2014.00012","volume":"8","author":"BM Campbell","year":"2014","unstructured":"Campbell BM, Charych E, Lee AW, M\u00f6ller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12.","journal-title":"Front Neurosci"},{"key":"913_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuropharm.2016.08.003","volume":"112","author":"R Schwarcz","year":"2017","unstructured":"Schwarcz R, Stone TW. The kynurenine pathway and the brain: challenges, controversies and promises. Neuropharmacology. 2017;112:237\u201347.","journal-title":"Neuropharmacology"},{"key":"913_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3389\/fpsyt.2018.00552","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu H, Ding L, Zhang H, Mellor D, Wu H, Zhao D, et al. The metabolic factor kynurenic acid of kynurenine pathway predicts major depressive disorder. Front Psychiatry. 2018;9:552.","journal-title":"Front Psychiatry"},{"key":"913_CR17","doi-asserted-by":"publisher","first-page":"463e71","DOI":"10.1038\/npp.2014.194","volume":"40","author":"J Savitz","year":"2015","unstructured":"Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowan PS, et al. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology. 2015;40:463e71.","journal-title":"Neuropsychopharmacology"},{"key":"913_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/srep17799","volume":"5","author":"F Fazio","year":"2016","unstructured":"Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, et al. Xanthurenic acid activates mGlu2\/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep. 2016;5:17799.","journal-title":"Sci Rep"},{"key":"913_CR19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4137\/IJTR.S4282","volume":"3","author":"LG Darlington","year":"2010","unstructured":"Darlington LG, Forrest CM, Mackay GM, Smith RA, Smith AJ, Stoy N, et al. On the biological importance of the 3-hydroxyanthranilic acid: anthranilic acid ratio. Int J Tryptophan Res. 2010;3:51\u20139.","journal-title":"Int J Tryptophan Res"},{"key":"913_CR20","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/0306-4522(94)90438-3","volume":"61","author":"RJ Beninger","year":"1994","unstructured":"Beninger RJ, Colton AM, Ingles JL, Jhamandas K, Boegman RJ. Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neuroscience. 1994;61:603\u201312.","journal-title":"Neuroscience"},{"key":"913_CR21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1111\/j.1742-4658.2012.08485.x","volume":"279","author":"GJ Guillemin","year":"2012","unstructured":"Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. FEBS J. 2012;279:1356\u201365.","journal-title":"FEBS J"},{"key":"913_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/bdi.12814","volume":"22","author":"S van den Ameele","year":"2020","unstructured":"van den Ameele S, van Nuijs ALN, Lai FY, Schuermans J, Verkerk R, van Diermen L, et al. A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder. Bipolar Disord. 2020;22:59\u201369.","journal-title":"Bipolar Disord"},{"key":"913_CR23","doi-asserted-by":"publisher","unstructured":"Kadriu B, Farmer CA, Yuan P, Park LT, Deng ZD, Moaddel R, et al. The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response. Mol Psychiatry. 2019. https:\/\/doi.org\/10.1038\/s41380-019-0589-8.","DOI":"10.1038\/s41380-019-0589-8"},{"key":"913_CR24","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2174\/1381612822666151214105314","volume":"22","author":"G Anderson","year":"2016","unstructured":"Anderson G, Jacob A, Bellivier F, Geoffroy PA. Bipolar disorder: the role of the kynurenine and melatonergic pathways. Curr Pharm Des. 2016;22:987\u20131012.","journal-title":"Curr Pharm Des"},{"key":"913_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.neuropharm.2016.05.020","volume":"112","author":"S Erhardt","year":"2017","unstructured":"Erhardt S, Schwieler L, Imbeault S, Engberg G. The kynurenine pathway in schizophrenia and bipolar disorder. Neuropharmacology. 2017;112:297\u2013306.","journal-title":"Neuropharmacology"},{"key":"913_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.neubiorev.2018.05.031","volume":"92","author":"D Arnone","year":"2018","unstructured":"Arnone D, Saraykar S, Salem H, Teixeira A, Dantzer R, Selvaraj S. Role of kynurenine pathway and its metabolites in mood disorders: a systematic review and meta-analysis of clinical studies. Neurosci Biobehav Rev. 2018;92:477\u201385.","journal-title":"Neurosci Biobehav Rev"},{"key":"913_CR27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1017\/S0033291719000400","volume":"50","author":"NE Steen","year":"2020","unstructured":"Steen NE, Dieset I, Hope S, Vedal TSJ, Smeland OB, Matson W, et al. Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. Psychol Med. 2020;50:595\u2013606.","journal-title":"Psychol Med"},{"key":"913_CR28","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"913_CR29","doi-asserted-by":"crossref","unstructured":"Lefebvre CJ, Glanville J, Briscoe S, Littlewood A, Marshall C, Metzendorf MI, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane handbook for systematic reviews of interventions, 2nd ed. Chichester, UK: Wiley; 2019. p. 67\u2013107.","DOI":"10.1002\/9781119536604.ch4"},{"key":"913_CR30","volume-title":"Practical meta-analysis","author":"M Lipsey","year":"2001","unstructured":"Lipsey M, Wilson D. Practical meta-analysis. Thousand Oaks, CA, USA: Sage; 2001."},{"key":"913_CR31","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane handbook for systematic reviews of interventions, 2nd ed. Chichester, UK: Wiley; 2019. p. 143\u201376.","DOI":"10.1002\/9781119536604.ch6"},{"key":"913_CR32","unstructured":"Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane handbook for systematic reviews of interventions, 2nd ed. Chichester, UK: Wiley; 2019. p. 67\u2013107."},{"key":"913_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"913_CR34","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/ije\/dyn065","volume":"37","author":"NA Patsopoulos","year":"2008","unstructured":"Patsopoulos NA, Evangelou E, Ioannidis JP. Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol. 2008;37:1148\u201357.","journal-title":"Int J Epidemiol"},{"key":"913_CR35","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"913_CR36","doi-asserted-by":"crossref","unstructured":"Page MJ, Higgins JPT, Sterne JAC. Chapter 13: Assessing risk of bias due to missing results in a synthesis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane handbook for systematic reviews of interventions, 2nd ed. Chichester, UK: Wiley; 2019. p. 349\u201374.","DOI":"10.1002\/9781119536604.ch13"},{"key":"913_CR37","unstructured":"StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC; 2017. https:\/\/www.stata.com\/."},{"key":"913_CR38","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.brs.2019.05.018","volume":"12","author":"TI Aarsland","year":"2019","unstructured":"Aarsland TI, Leskauskaite I, Midttun O, Ulvik A, Ueland PM, Oltedal L, et al. The effect of electroconvulsive therapy (ECT) on serum tryptophan metabolites. Brain Stimul. 2019;12:1135\u201342.","journal-title":"Brain Stimul"},{"key":"913_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.133","volume":"6","author":"L Brundin","year":"2016","unstructured":"Brundin L, Sellgren CM, Lim CK, Grit J, P\u00e5lsson E, Land\u00e9n M, et al. An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Transl Psychiatry. 2016;6:e865.","journal-title":"Transl Psychiatry"},{"key":"913_CR40","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.euroneuro.2005.06.003","volume":"16","author":"R Hoekstra","year":"2006","unstructured":"Hoekstra R, Fekkes D, Loonen AJ, Pepplinkhuizen L, Tuinier S, Verhoeven WM. Bipolar mania and plasma amino acids: increased levels of glycine. Eur Neuropsychopharmacol. 2006;16:71\u20137.","journal-title":"Eur Neuropsychopharmacol"},{"key":"913_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/bdi.12529","volume":"20","author":"D Mukherjee","year":"2018","unstructured":"Mukherjee D, Krishnamurthy VB, Millett CE, Reider A, Can A, Groer M, et al. Total sleep time and kynurenine metabolism associated with mood symptom severity in bipolar disorder. Bipolar Disord. 2018;20:27\u201334.","journal-title":"Bipolar Disord"},{"key":"913_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jad.2006.12.008","volume":"102","author":"AM Myint","year":"2007","unstructured":"Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007;102:65\u201372.","journal-title":"J Affect Disord"},{"key":"913_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0183-x","volume":"8","author":"JX Pan","year":"2018","unstructured":"Pan JX, Xia JJ, Deng FL, Liang WW, Wu J, Yin BM, et al. Diagnosis of major depressive disorder based on changes in multiple plasma neurotransmitters: a targeted metabolomics study. Transl Psychiatry. 2018;8:130.","journal-title":"Transl Psychiatry"},{"key":"913_CR44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.psyneuen.2017.04.015","volume":"81","author":"M Platzer","year":"2017","unstructured":"Platzer M, Dalkner N, Fellendorf FT, Birner A, Bengesser SA, Queissner R, et al. Tryptophan breakdown and cognition in bipolar disorder. Psychoneuroendocrinology. 2017;81:144\u201350.","journal-title":"Psychoneuroendocrinology"},{"key":"913_CR45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00406-016-0731-4","volume":"268","author":"S Poletti","year":"2018","unstructured":"Poletti S, Myint AM, Schuetze G, Bollettini I, Mazza E, Grillitsch D, et al. Kynurenine pathway and white matter microstructure in bipolar disorder. Eur Arch Psychiatry Clin Neurosci. 2018;268:157\u201368.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"913_CR46","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jad.2019.08.034","volume":"259","author":"S Poletti","year":"2019","unstructured":"Poletti S, Melloni E, Aggio V, Colombo C, Valtorta F, Benedetti F, et al. Grey and white matter structure associates with the activation of the tryptophan to kynurenine pathway in bipolar disorder. J Affect Disord. 2019;259:404\u201312.","journal-title":"J Affect Disord"},{"key":"913_CR47","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000491604","volume":"77","author":"M Pompili","year":"2019","unstructured":"Pompili M, Lionetto L, Curto M, Forte A, Erbuto D, Montebovi F, et al. Tryptophan and kynurenine metabolites: are they related to depression? Neuropsychobiology. 2019;77:23\u20138.","journal-title":"Neuropsychobiology"},{"key":"913_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.psyneuen.2014.11.015","volume":"52","author":"J Savitz","year":"2015","unstructured":"Savitz J, Dantzer R, Wurfel BE, Victor TA, Ford BN, Bodurka J, et al. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology. 2015;52:200\u201311.","journal-title":"Psychoneuroendocrinology"},{"key":"913_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0378-9","volume":"9","author":"CM Sellgren","year":"2019","unstructured":"Sellgren CM, Gracias J, Jungholm O, Perlis RH, Engberg G, Schwieler L, et al. Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls. Transl Psychiatry. 2019;9:37.","journal-title":"Transl Psychiatry"},{"key":"913_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.bbacli.2016.03.008","volume":"5","author":"N Yoshimi","year":"2016","unstructured":"Yoshimi N, Futamura T, Kakumoto K, Salehi AM, Sellgren CM, Holmen-Larsson J. Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder. BBA Clin. 2016;5:151\u20138.","journal-title":"BBA Clin"},{"key":"913_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbi.2017.08.024","volume":"67","author":"TB Meier","year":"2018","unstructured":"Meier TB, Drevets WC, Teague TK, Wurfel BE, Mueller SC, Bodurka J, et al. Kynurenic acid is reduced in females and oral contraceptive users: implications for depression. Brain Behav Immun. 2018;67:59\u201364.","journal-title":"Brain Behav Immun"},{"key":"913_CR52","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/bdi.12166","volume":"16","author":"EZ Reininghaus","year":"2014","unstructured":"Reininghaus EZ, McIntyre RS, Reininghaus B, Geisler S, Bengesser SA, Lackner N, et al. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2014;16:432\u201340.","journal-title":"Bipolar Disord"},{"key":"913_CR53","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fpsyt.2018.00250","volume":"9","author":"S van den Ameele","year":"2018","unstructured":"van den Ameele S, Fuchs D, Coppens V, de Boer P, Timmers M, Sabbe B, et al. Markers of inflammation and monoamine metabolism indicate accelerated aging in bipolar disorder. Front Psychiatry. 2018;9:250.","journal-title":"Front Psychiatry"},{"key":"913_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.88","volume":"7","author":"BE Wurfel","year":"2017","unstructured":"Wurfel BE, Drevets WC, Bliss SA, McMillin JR, Suzuki H, Ford BN, et al. Serum kynurenic acid is reduced in affective psychosis. Transl Psychiatry. 2017;7:e1115.","journal-title":"Transl Psychiatry"},{"key":"913_CR55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.neulet.2008.06.007","volume":"441","author":"TJ Connor","year":"2008","unstructured":"Connor TJ, Starr N, O\u2019Sullivan JB, Harkin A. Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma? Neurosci Lett. 2008;441:29\u201334.","journal-title":"Neurosci Lett"},{"key":"913_CR56","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.euroneuro.2013.03.008","volume":"23","author":"R Molteni","year":"2013","unstructured":"Molteni R, Macchi F, Zecchillo C, Dell\u2019Agli M, Colombo E, Calabrese F, et al. Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine. Eur Neuropsychopharmacol. 2013;23:1645\u20132655.","journal-title":"Eur Neuropsychopharmacol"},{"key":"913_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.bbi.2014.07.012","volume":"43","author":"C Bay-Richter","year":"2015","unstructured":"Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Tr\u00e4skman-Bendz L, Guillemin GJ, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain Behav Immun. 2015;43:110\u20137.","journal-title":"Brain Behav Immun"},{"key":"913_CR58","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/mp.2009.116","volume":"15","author":"CL Raison","year":"2010","unstructured":"Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G, et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2010;15:393\u2013403.","journal-title":"Mol Psychiatry"},{"key":"913_CR59","doi-asserted-by":"publisher","unstructured":"Kindler J, Lim CK, Weickert CS, Boerrigter D, Galletly C, Liu D, et al. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry. 2019. https:\/\/doi.org\/10.1038\/s41380-019-0401-9.","DOI":"10.1038\/s41380-019-0401-9"},{"key":"913_CR60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41386-020-0607-1","volume":"45","author":"E Haroon","year":"2020","unstructured":"Haroon E, Welle JR, Woolwine BJ, Goldsmith DR, Baer W, Patel T, et al. Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacol. 2020;45:998\u20131007.","journal-title":"Neuropsychopharmacol"},{"key":"913_CR61","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/schbul\/sbx035","volume":"44","author":"AK Wang","year":"2018","unstructured":"Wang AK, Miller BJ. Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression. Schizophr Bull. 2018;44:75\u201383.","journal-title":"Schizophr Bull"},{"key":"913_CR62","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences, 2nd ed. Hillsdale, NJ, USA: LEA; 1988."},{"key":"913_CR63","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/schbul\/sbw221","volume":"43","author":"E Plitman","year":"2017","unstructured":"Plitman E, Iwata Y, Caravaggio F, Nakajima S, Chung JK, Gerretsen P, et al. Kynurenic acid in Schizophrenia: A Systematic Review and Meta-analysis. Schizophr Bull. 2017;43:764\u201377.","journal-title":"Schizophr Bull"},{"key":"913_CR64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.neubiorev.2018.03.023","volume":"90","author":"K Ogyu","year":"2018","unstructured":"Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:16\u201325.","journal-title":"Neurosci Biobehav Rev"},{"key":"913_CR65","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.neuropharm.2016.01.034","volume":"112","author":"EY Bryleva","year":"2017","unstructured":"Bryleva EY, Brundin L. Kynurenine pathway metabolites and suicidality. Neuropharmacology. 2017;112:324\u201330.","journal-title":"Neuropharmacology"},{"key":"913_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.neuroscience.2012.12.052","volume":"234","author":"P Maciejak","year":"2013","unstructured":"Maciejak P, Szyndler J, Turzy\u0144ska D, Sobolewska A, Ko\u0142osowska K, Lehner M, et al. The kynurenine pathway: a missing piece in the puzzle of valproate action? Neuroscience. 2013;234:135\u201345.","journal-title":"Neuroscience"},{"key":"913_CR67","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.bbi.2011.05.005","volume":"25","author":"AM Myint","year":"2011","unstructured":"Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharp\u00e9 S, et al. Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-na\u00efve and medication-free schizophrenic patients. Brain Behav Immun. 2011;25:1576\u201381.","journal-title":"Brain Behav Immun"},{"key":"913_CR68","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1176\/appi.ajp.2013.13040447","volume":"170","author":"F Bartoli","year":"2013","unstructured":"Bartoli F, Carr\u00e0 G, Crocamo C, Carretta D, Clerici M. Bipolar disorder, schizophrenia, and metabolic syndrome. Am J Psychiatry. 2013;170:927\u20138.","journal-title":"Am J Psychiatry"},{"key":"913_CR69","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.psyneuen.2015.10.014","volume":"63","author":"M Belvederi Murri","year":"2016","unstructured":"Belvederi Murri M, Prestia D, Mondelli V, Pariante C, Patti S, Olivieri B, et al. The HPA axis in bipolar disorder: Systematic review and meta-analysis. Psychoneuroendocrinology. 2016;63:327\u201342.","journal-title":"Psychoneuroendocrinology"},{"key":"913_CR70","doi-asserted-by":"publisher","unstructured":"Misiak B, Bartoli F, Carr\u00e0 G, Ma\u0142ecka M, Samochowiec J, Jarosz K, et al. Chemokine alterations in bipolar disorder: a systematic review and meta-analysis. Brain Behav Immun. 2020. https:\/\/doi.org\/10.1016\/j.bbi.2020.04.013.","DOI":"10.1016\/j.bbi.2020.04.013"},{"key":"913_CR71","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jad.2012.06.010","volume":"144","author":"K Munkholm","year":"2013","unstructured":"Munkholm K, Vinberg M, Vedel Kessing L. Cytokines in bipolar disorder: a systematic review and meta-analysis. J Affect Disord. 2013;144:16\u201327.","journal-title":"J Affect Disord"},{"key":"913_CR72","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","volume":"22","author":"B Kadriu","year":"2019","unstructured":"Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate CA Jr. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments. Int J Neuropsychopharmacol. 2019;22:119\u201335.","journal-title":"Int J Neuropsychopharmacol"},{"key":"913_CR73","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793\u2013802.","journal-title":"Arch Gen Psychiatry"},{"key":"913_CR74","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","volume":"71","author":"CA Zarate Jr","year":"2012","unstructured":"Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine\u2019s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71:939\u201346.","journal-title":"Biol Psychiatry"},{"key":"913_CR75","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.neubiorev.2017.03.010","volume":"77","author":"F Bartoli","year":"2017","unstructured":"Bartoli F, Riboldi I, Crocamo C, Di Brita C, Clerici M, Carr\u00e0 G. Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis. Neurosci Biobehav Rev. 2017;77:232\u20136.","journal-title":"Neurosci Biobehav Rev"},{"key":"913_CR76","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/0004867419894064","volume":"54","author":"F Bartoli","year":"2020","unstructured":"Bartoli F, Wilkinson ST. Ketamine and esketamine for suicidal ideation: recent progress and practical issues. Aust N Z J Psychiatry. 2020;54:206\u20137.","journal-title":"Aust N Z J Psychiatry"},{"key":"913_CR77","doi-asserted-by":"publisher","unstructured":"Park LT, Kadriu B, Gould TD, Zanos P, Greenstein D, Evans JW, et al. Randomized trial of the N-methyl-d-aspartate receptor glycine site antagonist prodrug 4-chlorokynurenine in treatment-resistant depression. Int J Neuropsychopharmacol. 2020. https:\/\/doi.org\/10.1093\/ijnp\/pyaa025.","DOI":"10.1093\/ijnp\/pyaa025"},{"key":"913_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neubiorev.2019.05.017","volume":"103","author":"F Bartoli","year":"2019","unstructured":"Bartoli F, Crocamo C, Carr\u00e0 G. Cannabis use disorder and suicide attempts in bipolar disorder: a meta-analysis. Neurosci Biobehav Rev. 2019;103:14\u201320.","journal-title":"Neurosci Biobehav Rev"},{"key":"913_CR79","doi-asserted-by":"publisher","unstructured":"Haggarty SJ, Karmacharya R, Perlis RH. Advances toward precision medicine for bipolar disorder: mechanisms & molecules. Mol Psychiatry. 2020. https:\/\/doi.org\/10.1038\/s41380-020-0831-4.","DOI":"10.1038\/s41380-020-0831-4"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-00913-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-00913-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-00913-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T22:56:47Z","timestamp":1634597807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-020-00913-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["913"],"URL":"https:\/\/doi.org\/10.1038\/s41380-020-00913-1","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]},"assertion":[{"value":"1 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}